The use of stem cells in the treatment of diabetic foot syndrome: analysis of clinical data (review)
https://doi.org/10.14341/serg12773
Abstract
Diabetic foot syndrome (DFS) is one of the most common complications of diabetes and is a consequence of pathological changes in the peripheral nervous system, microcirculatory bed, as well as the osteoarticular apparatus of the foot, which poses a threat to the development of ulcerative necrotic processes and gangrene. It is reported that approximately 15% of patients with DM develop SDS, of which 14 to 24% undergo limb amputation. SDS also contributes significantly to early mortality, as 68% of amputees die within 5 years. The authors conducted an electronic search for publications in the PubMed and Elibrary databases. Stem cell therapy has been used as adjuvant therapy in the treatment of SDS. The results presented in this study demonstrate that the use of mesenchymal stem cells is safe and effective without clinically significant side effects and, therefore, can help prevent high limb amputations in uncomplicated diabetic foot ulcers. However, there are still a number of problems with the coordination of the most applicable type of cells, the method of their administration and dosages, which requires further research.
About the Authors
A. I. Batraeva
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Aliya I. Batraeva.
450008, Ufa, Lenin st., 3
Competing Interests:
None
V. V. Burlyaeva
A.I. Evdokimov Moscow State Medical and Dental University
Russian Federation
Competing Interests:
Russian Federation
Valeriya V. Burlyaeva.
Moscow
Competing Interests:
None
I. V. Mudrik
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Ivan V. Mudrik.
Ufa
Competing Interests:
None
S. S. Sinakaeva
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Sabina S. Sinakaeva.
Ufa
Competing Interests:
None
D. I. Degtyareva
A.I. Evdokimov Moscow State Medical and Dental University
Russian Federation
Competing Interests:
Russian Federation
Darya I. Degtyareva.
Moscow
Competing Interests:
None
V. V. Salimov
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Vadim V. Salimov.
Ufa
Competing Interests:
None
References
1. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104-123. (In Russ.) doi: https://doi.org/10.14341/DM13035
2. Bordyugov PS, Parshikov MV. Deformities of the feet in patients with diabetic foot syndrome (literature review). Genij ortopedii. 2022;28(3):452-458 (In Russ.)
3. Levy N, Gillibrand W. Management of diabetic foot ulcers in the community: an update. Br J Community Nurs. 2019;24(3):14-19. doi: https://doi.org/10.12968/bjcn.2019.24.Sup3.S14
4. Nascimento de Aquino MJ, Caetano de Souza AC, Pereira Borges JW, da Silva Negreiros FD, de Sousa Gonçalves M, Oliveira Martins PM, Magalhães Moreira TM. Prevalence, Incidence and Factors Associated with Diabetic Foot in People with Type 2 Diabetes: Systematic Review with Meta-Analysis. Curr Diabetes Rev. 2023. doi: https://doi.org/10.2174/1573399819666230407093450
5. Kozlova AA, Vlasov TD, Davydenko VV. Influence of cell and gene therapy on the healing of trophic ulcers in patients with neuroischemic form of diabetic foot syndrome. Surgical practice. 2016;(2):32-38 (In Russ.)
6. Makarov SV, Muselimyan NH. Contribution of regenerative medicine to the therapy of autoimmune diseases of the nervous system. Genes & Cells. 2022;17(3):141-142. (In Russ.)
7. Shu X, Shu S, Tang S, Yang L, Liu D, Li K, et al. Efficiency of stem cell based therapy in the treatment of diabetic foot ulcer: a meta-analysis. Endocr J. 2018;65(4):403-413. doi: https://doi.org/10.1507/endocrj.EJ17-0424.
8. Kalinin RE, Suchkov IA, Mzhavanadze ND, Krylov AA, Isaev AA, Plaksa IL, Deev RV. Regenerative technologies in treatment of diabetic foot ulcers. Genes & Cells. 2017;12(1):15-26. (In Russ.) doi: https://doi.org/10.23868/gc120634
9. Lyundup AV, Maksimova NV, Mel’nichenko GA, Pomytkin IA, Klabukov ID. Autologichnye mezenkhimal’nye stvolovye kletki kak effektivnyy aktivator epitelizatsii pri sindrome diabeticheskoy stopy. Genes & Cells. 2017;12(3):150-151 (In Russ.). doi: https://doi.org/10.23868/gc121002
10. Yu Q, Qiao GH, Wang M, Yu L, Sun Y, Shi H, Ma TL. Stem Cell-Based Therapy for Diabetic Foot Ulcers. Front Cell Dev Biol. 2022;10:812262. doi: https://doi.org/10.3389/fcell.2022.812262
11. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155-2160. doi: https://doi.org/10.2337/diacare.28.9.2155
12. Procházka V, Gumulec J, Jalůvka F, Salounová D, Jonszta T, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant. 2010;19(11):1413-1424. doi: https://doi.org/10.3727/096368910X514170
13. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009;12(5):359-366. doi: https://doi.org/10.1089/rej.2009.0872
14. Jain P, Perakath B, Jesudason MR, Nayak S. The effect of autologous bone marrow-derived cells on healing chronic lower extremity wounds: results of a randomized controlled study. Ostomy Wound Manage. 2011;57(7):38-44
15. Maksimova N, Krasheninnikov M, Zhang Y, Ponomarev E, Pomytkin I, et al. Early passage autologous mesenchymal stromal cells accelerate diabetic wound re-epithelialization: A clinical case study. Cytotherapy. 2017;19(12):1548-1550 doi: https://doi.org/10.1016/j.jcyt.2017.08.017
16. Maksimova NV, Michenko AV, Krasilnikova OA, et al. Mesenchymal stromal cells therapy alone does not lead to the complete restoration of the skin parameters in diabetic foot patients within a 3-year follow-up period. BioImpacts. September 2021. doi: https://doi.org/10.34172/bi.2021.22167
17. Ganina AM, Askarov MB. The use of mesenchymal stem cells in the treatment of type 1 diabetes mellitus and its complications. Universum: Medicine and Pharmacology. 2022;4(87):4-6. (In Russ.)
18. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92(1):26-36. doi: https://doi.org/10.1016/j.diabres.2010.12.010
19. Kirana S, Stratmann B, Prante C, Prohaska W, Koerperich H, et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract. 2012;66(4):384-393. doi: https://doi.org/10.1111/j.1742-1241.2011.02886.x
20. Moon KC, Suh HS, Kim KB, Han SK, Young KW, Lee JW, Kim MH. Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers. Diabetes. 2019;68(4):837-846. doi: https://doi.org/10.2337/db18-0699
21. Uzun E, Güney A, Gönen ZB, Özkul Y, Kafadar İH, Günay M, Mutlu M. Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study. Foot Ankle Surg. 2021;27(6):636-642. doi: https://doi.org/10.1016/j.fas.2020.08.002
22. Han SK, Kim HR, Kim WK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010;18(4):342-348. doi: https://doi.org/10.1111/j.1524-475X.2010.00593.x
23. Rai V, Moellmer R, Agrawal DK. Stem Cells and Angiogenesis: Implications and Limitations in Enhancing Chronic Diabetic Foot Ulcer Healing. Cells. 2022;11(15):2287. doi: https://doi.org/10.3390/cells11152287
24. Nalisa DL, Moneruzzaman M, Changwe GJ, Mobet Y, Li LP, Ma YJ, Jiang HW. Stem Cell Therapy for Diabetic Foot Ulcers: Theory and Practice. J Diabetes Res. 2022;2022:6028743. doi: https://doi.org/10.1155/2022/6028743
25. Liu R, Dong R, Chang M, Liang X, Wang HC. Adipose-Derived Stem Cells for the Treatment of Diabetic Wound: From Basic Study to Clinical Application. Front Endocrinol (Lausanne). 2022;13:882469. doi: https://doi.org/10.3389/fendo.2022.882469
26. Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol. 2019;10:1191. doi: https://doi.org/10.3389/fimmu.2019.01191
27. Guillamat-Prats R. The Role of MSC in Wound Healing, Scarring and Regeneration. Cells. 2021;10(7):1729. doi: https://doi.org/10.3390/cells10071729
Supplementary files
Review
For citations:
Batraeva A.I., Burlyaeva V.V., Mudrik I.V., Sinakaeva S.S., Degtyareva D.I., Salimov V.V. The use of stem cells in the treatment of diabetic foot syndrome: analysis of clinical data (review). Endocrine Surgery. 2025;19(1):5-12. (In Russ.) https://doi.org/10.14341/serg12773
Views:
661
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
